{"preliminary_commentary":{"by_channel":{"youtube":11,"x_thread":5,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05721248\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"STOP-HER2","nct_id":"NCT05721248","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=stop-her2-nct05721248. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will have scans 30 days prior to starting study then undergo clinical follow-up 4-6 weeks after study initiation, at 12 weeks, and every 12 weeks thereafter. Visits will include interval history, physical exam, concomitant medications and blood draw for tumor marker assessment and research blood.\n\nParticipants will undergo restaging scans every 12 weeks (+/- 2 weeks).","label":"Cohort 1: Observational Continue Anti-HER2 Therapy","type":"NO_INTERVENTION"},{"description":"Participants will have scans 30 days prior to starting study. Week 1 participants will stop anti-HER2 therapy then undergo clinical follow-up every 4-6 weeks, at 12 weeks, and every 12 weeks thereafter. Visits will include interval history, physical exam, concomitant medications and blood draw for tumor marker assessment and research blood.\n\nParticipants will undergo restaging scans every 12 weeks (+/- 2 weeks). Participants remaining progression-free after one year off treatment, may continue off anti-HER2 therapy indefinitely, with imaging surveillance suggested to be every 3-6 months at the discretion of the treating oncologist and will be followed up to 10 years Participants with disease progression after stopping anti-HER2 therapy, treatment is at discretion of the treating physician but resuming the pre-study regimen is strongly encouraged.","label":"Cohort 2: - Stop Anti-HER2 Therapy","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)","Gateway for Cancer Research","Susan G. Komen Breast Cancer Foundation","Translational Breast Cancer Research Consortium","Johns Hopkins University"],"completion_date":{"date":"2036-06","type":"ESTIMATED"},"conditions":["Breast Cancer","Metastatic Breast Cancer","HER2-positive Breast Cancer"],"enrollment":{"count":82,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Cessation of anti-HER2 treatment","otherNames":[],"type":"OTHER"}],"last_update":"2026-08-06","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients With HER2+ Metastatic Breast Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-06-22","type":"ACTUAL"},"primary_outcomes":[{"measure":"1-year progression-free survival (PFS) Stopped Anti-HER2 Treatment","timeFrame":"Up to 1 year"},{"measure":"1-year progression-free survival (PFS) Continued Anti-HER2 Treatment","timeFrame":"Up to 1 year"}],"references":[],"start_date":{"date":"2023-04-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"STOP-HER2: Stopping Trastuzumab in HER2+ MBC","url":"https://clinicaltrials.gov/study/NCT05721248"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/stop-her2-nct05721248"}